Cargando…

Complete response in a patient with liver metastases from breast cancer employing hepatic arterial infusion 5-fluorouracil based chemotherapy plus systemic nab-paclitaxel

About half of patients with metastatic breast cancer (mBC) have unresectable liver metastases (LMs) or liver-predominant disease (LPD). Unfortunately systemic chemotherapy has limited tumor response due to LMs are supplied by hepatic artery. Hepatic intra-arterial (HAI) have antitumor activity in pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Ranieri, Girolamo, Marech, Ilaria, Porcelli, Mariangela, Giotta, Francesco, Palmiotti, Gennaro, Laricchia, Giuseppe, Fazio, Vito, Gadaleta, Cosmo Damiano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5814293/
https://www.ncbi.nlm.nih.gov/pubmed/29487726
http://dx.doi.org/10.18632/oncotarget.23793
_version_ 1783300321630486528
author Ranieri, Girolamo
Marech, Ilaria
Porcelli, Mariangela
Giotta, Francesco
Palmiotti, Gennaro
Laricchia, Giuseppe
Fazio, Vito
Gadaleta, Cosmo Damiano
author_facet Ranieri, Girolamo
Marech, Ilaria
Porcelli, Mariangela
Giotta, Francesco
Palmiotti, Gennaro
Laricchia, Giuseppe
Fazio, Vito
Gadaleta, Cosmo Damiano
author_sort Ranieri, Girolamo
collection PubMed
description About half of patients with metastatic breast cancer (mBC) have unresectable liver metastases (LMs) or liver-predominant disease (LPD). Unfortunately systemic chemotherapy has limited tumor response due to LMs are supplied by hepatic artery. Hepatic intra-arterial (HAI) have antitumor activity in pretreated patients with LMs. Here we report the case of a 55-year-old woman affected by BCLPD and heavily pretreated. LMs responded to treatment based on HAI with 5-fluorouracil and nab-paclitaxel systemic chemotherapy, and they completely disappeared on a CT-scan. We conclude that this combination chemotherapy is safe and may be very useful for the treatment of patients with BCLPD. Therefore, this combination should be evaluated in a large study.
format Online
Article
Text
id pubmed-5814293
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-58142932018-02-27 Complete response in a patient with liver metastases from breast cancer employing hepatic arterial infusion 5-fluorouracil based chemotherapy plus systemic nab-paclitaxel Ranieri, Girolamo Marech, Ilaria Porcelli, Mariangela Giotta, Francesco Palmiotti, Gennaro Laricchia, Giuseppe Fazio, Vito Gadaleta, Cosmo Damiano Oncotarget Case Report About half of patients with metastatic breast cancer (mBC) have unresectable liver metastases (LMs) or liver-predominant disease (LPD). Unfortunately systemic chemotherapy has limited tumor response due to LMs are supplied by hepatic artery. Hepatic intra-arterial (HAI) have antitumor activity in pretreated patients with LMs. Here we report the case of a 55-year-old woman affected by BCLPD and heavily pretreated. LMs responded to treatment based on HAI with 5-fluorouracil and nab-paclitaxel systemic chemotherapy, and they completely disappeared on a CT-scan. We conclude that this combination chemotherapy is safe and may be very useful for the treatment of patients with BCLPD. Therefore, this combination should be evaluated in a large study. Impact Journals LLC 2017-12-31 /pmc/articles/PMC5814293/ /pubmed/29487726 http://dx.doi.org/10.18632/oncotarget.23793 Text en Copyright: © 2018 Ranieri et al. http://creativecommons.org/licenses/by/3.0/ This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) (CC-BY), which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Case Report
Ranieri, Girolamo
Marech, Ilaria
Porcelli, Mariangela
Giotta, Francesco
Palmiotti, Gennaro
Laricchia, Giuseppe
Fazio, Vito
Gadaleta, Cosmo Damiano
Complete response in a patient with liver metastases from breast cancer employing hepatic arterial infusion 5-fluorouracil based chemotherapy plus systemic nab-paclitaxel
title Complete response in a patient with liver metastases from breast cancer employing hepatic arterial infusion 5-fluorouracil based chemotherapy plus systemic nab-paclitaxel
title_full Complete response in a patient with liver metastases from breast cancer employing hepatic arterial infusion 5-fluorouracil based chemotherapy plus systemic nab-paclitaxel
title_fullStr Complete response in a patient with liver metastases from breast cancer employing hepatic arterial infusion 5-fluorouracil based chemotherapy plus systemic nab-paclitaxel
title_full_unstemmed Complete response in a patient with liver metastases from breast cancer employing hepatic arterial infusion 5-fluorouracil based chemotherapy plus systemic nab-paclitaxel
title_short Complete response in a patient with liver metastases from breast cancer employing hepatic arterial infusion 5-fluorouracil based chemotherapy plus systemic nab-paclitaxel
title_sort complete response in a patient with liver metastases from breast cancer employing hepatic arterial infusion 5-fluorouracil based chemotherapy plus systemic nab-paclitaxel
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5814293/
https://www.ncbi.nlm.nih.gov/pubmed/29487726
http://dx.doi.org/10.18632/oncotarget.23793
work_keys_str_mv AT ranierigirolamo completeresponseinapatientwithlivermetastasesfrombreastcanceremployinghepaticarterialinfusion5fluorouracilbasedchemotherapyplussystemicnabpaclitaxel
AT marechilaria completeresponseinapatientwithlivermetastasesfrombreastcanceremployinghepaticarterialinfusion5fluorouracilbasedchemotherapyplussystemicnabpaclitaxel
AT porcellimariangela completeresponseinapatientwithlivermetastasesfrombreastcanceremployinghepaticarterialinfusion5fluorouracilbasedchemotherapyplussystemicnabpaclitaxel
AT giottafrancesco completeresponseinapatientwithlivermetastasesfrombreastcanceremployinghepaticarterialinfusion5fluorouracilbasedchemotherapyplussystemicnabpaclitaxel
AT palmiottigennaro completeresponseinapatientwithlivermetastasesfrombreastcanceremployinghepaticarterialinfusion5fluorouracilbasedchemotherapyplussystemicnabpaclitaxel
AT laricchiagiuseppe completeresponseinapatientwithlivermetastasesfrombreastcanceremployinghepaticarterialinfusion5fluorouracilbasedchemotherapyplussystemicnabpaclitaxel
AT faziovito completeresponseinapatientwithlivermetastasesfrombreastcanceremployinghepaticarterialinfusion5fluorouracilbasedchemotherapyplussystemicnabpaclitaxel
AT gadaletacosmodamiano completeresponseinapatientwithlivermetastasesfrombreastcanceremployinghepaticarterialinfusion5fluorouracilbasedchemotherapyplussystemicnabpaclitaxel